LXRX · Lexicon Pharmaceuticals, Inc. · Documents

Nov 22

Earnings call

Q3 2024 earnings call

Nov 22

Current report 8-K

Exit or restructuring costs

Nov 20

Current report 8-K Events of Nov 19

Director or officer change, or executive pay

Nov 13

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $1.75M ▲ 980.2% Net loss $64.81M Diluted EPS -$0.18

Nov 12

Current report 8-K

Financial results

Oct 16

Current report 8-K

Entered into a material agreement

Sep 16

Current report 8-K Events of Sep 13

Director or officer change, or executive pay

Aug 2

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $1.65M ▲ 419.6% Net loss $53.43M Diluted EPS -$0.17

Aug 2

Registration statement S-3

Registration statement

Aug 1

Earnings call

Q2 2024 earnings call

Aug 1

Current report 8-K

Financial results

Jul 8

Current report 8-K Events of Jul 3

Director or officer change, or executive pay

Jul 1

Current report 8-K Events of Jun 28

Entered into a material agreement

May 10

Current report 8-K

Unregistered sale of equity, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

May 10

Registration statement S-3/A

Registration statement

May 2

Earnings call

Q1 2024 earnings call

May 2

Current report 8-K

Financial results

May 2

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $1.13M ▲ 4608.3% Net loss $48.4M Diluted EPS -$0.20

Apr 29

Current report 8-K

Director or officer change, or executive pay

Mar 26

Proxy statement DEF 14A

Proxy statement

Mar 26

Annual report to holders ARS

Annual report to holders

Mar 26

Proxy statement DEFA14A

Proxy statement

Mar 25

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $1.2M ▲ 766.2% Net loss $177.12M Diluted EPS -$0.80

Mar 25

Registration statement S-3

Registration statement

Mar 12

Current report 8-K

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Mar 11

Current report 8-K Events of Mar 6

Entered into a material agreement, Financial results, Unregistered sale of equity, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure

Mar 11

Proxy statement PRE 14A

Proxy statement

Dec 29

Current report 8-K

Entered into a material agreement

Dec 29

Current report 8-K

Entered into a material agreement

Nov 8

Earnings call

Q3 2023 earnings call

Nov 8

Current report 8-K

Financial results

Nov 8

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $162K ▲ 315.4% Net loss $50.53M Diluted EPS -$0.21

Oct 11

Current report 8-K Events of Oct 9

Director or officer change, or executive pay

Aug 4

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $317K ▲ 805.7% Net loss $44.9M

Aug 3

Earnings call

Q2 2023 earnings call

Aug 3

Current report 8-K

Financial results

Jul 31

Current report 8-K Events of Jul 27

Director or officer change, or executive pay

Jul 24

Current report 8-K Events of Jul 18

Director or officer change, or executive pay

Jun 28

Current report 8-K Events of Jun 23

New debt or off-balance-sheet obligation, Unregistered sale of equity

Jun 2

Current report 8-K Events of May 31

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

May 31

Current report 8-K

Regulation FD disclosure, Other events

May 8

Current report 8-K/A Events of Apr 27

Shareholder vote results

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $31.93M

May 2

Earnings call

Q1 2023 earnings call

May 2

Current report 8-K

Financial results

May 2

Current report 8-K Events of May 1

Entered into a material agreement

Apr 27

Current report 8-K

Entered into a material agreement, Shareholder vote results

Mar 17

Proxy statement DEF 14A

Proxy statement

Mar 17

Proxy statement DEFA14A

Proxy statement

Mar 3

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $139K ▼ 53.4% Net loss $101.94M